Patents Assigned to Regis University
  • Patent number: 9394254
    Abstract: This invention provides a family of compounds that inhibit Class II fructose 1,6-bisphosphate aldolase (FBA), which is implicated in the pathogenic activity of a broad range of bacterial and parasitic agents. The compounds were identified by empirical testing, and provide a basis for further derivatization and optimization of 8-hydroxyquinoline-2-carboxylic acid and related compounds. Crystal structure shows that the compounds don't bind directly to the catalytic site of the enzyme, and so are not defined simply as substrate analogs. Instead, they create a pocket by induced fit, resulting a powerful and specific inhibitory effect on FBA activity.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: July 19, 2016
    Assignee: The University of Denver and Regis University
    Inventors: Scott Dusan Pegan, Kateri Ahrendt, Glenn C. Capodagli, Bryan Cowen
  • Publication number: 20140336221
    Abstract: This invention provides a family of compounds that inhibit Class II fructose 1,6-bisphosphate aldolase (FBA), which is implicated in the pathogenic activity of a broad range of bacterial and parasitic agents. The compounds were identified by empirical testing, and provide a basis for further derivatization and optimization of 8-hydroxyquinoline-2-carboxylic acid and related compounds. Crystal structure shows that the compounds don't bind directly to the catalytic site of the enzyme, and so are not defined simply as substrate analogs. Instead, they create a pocket by induced fit, resulting a powerful and specific inhibitory effect on FBA activity.
    Type: Application
    Filed: May 8, 2014
    Publication date: November 13, 2014
    Applicants: Colorado Seminary, Which Owns and Operates The University Of Denver, Regis University
    Inventors: Scott Dusan Pegan, Kateri Ahrendt, Glenn C. Capodagli, Bryan Cowen